Boehringer Ingelheim

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Saiba Animal Health is a biotechnology company dedicated to developing innovative therapeutic drugs and vaccines aimed at improving the well-being and quality of life for dogs and their owners. Utilizing a recombinant virus-like particle vaccine platform, the company focuses on creating therapeutic vaccines that induce long-lasting antibodies targeting key molecules associated with chronic diseases. This approach allows veterinarians to provide effective relief for various conditions, including allergies, inflammation, pain, nervous system disorders, and cancer, ultimately enhancing the health and comfort of pets.

Nerio Therapeutics is a biotechnology company focused on the life sciences sector. It was founded in 2019 and is based in La Jolla, CA, USA.

Shengbao Bio is committed to the development of novel live bacterial medications, leveraging gene circuits and precise regulation of gene and payload expression.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Ilara Health is a company based in Nairobi, Kenya, founded in 2018, that specializes in the development and distribution of AI-powered diagnostic devices aimed at primary care doctors in peri-urban and rural clinics. The company's innovative technology platform integrates miniature diagnostic devices with software that connects to an electronic medical record system, allowing healthcare providers to efficiently manage patient data. By focusing on accurate and affordable diagnostics, Ilara Health seeks to enhance healthcare accessibility and quality for rural populations in Africa, addressing the challenges posed by a fragmented healthcare infrastructure.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Actym Therapeutics, Inc. is an immunotherapy company based in Berkeley, California, dedicated to the discovery and development of innovative therapies for cancer treatment. Founded in 2017, the company has developed a unique microbial-based immunotherapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy). This platform is designed to specifically target and enrich within various solid tumors while sparing healthy tissues. In preclinical studies, STACT has shown the capability to deliver multiplexed immuno-modulatory payloads directly to immune cells residing within tumors. This approach addresses significant challenges faced by conventional therapies, particularly systemic toxicities associated with intravenous dosing. By combining multiple payloads within a single therapy, STACT aims to engage various biological pathways, potentially enhancing treatment efficacy. Actym's commitment to overcoming the limitations of existing cancer therapies positions it as a promising player in the biopharmaceutical field.

TeleVet, Inc. operates a mobile application designed to facilitate remote communication between pet owners and veterinarians. The application enables users to schedule virtual consultations, book follow-up appointments, and receive care through text, call, and video chat. It also supports veterinarians by providing tools for appointment scheduling, telemedicine services, and digital prescriptions, integrating seamlessly with existing veterinary practice management systems. Additionally, the app offers automated communication features, such as email templates and social media posts, to enhance client engagement regarding pet health services. Founded in 2015 and based in Austin, Texas, TeleVet, Inc. was previously known as Horse Facts, Inc. before rebranding in January 2016. The application is available for download on both the App Store and Google Play.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

C-mo Medical Solutions specializes in developing innovative monitoring devices aimed at comprehensively assessing patients' cough patterns. The company's portable and ergonomic wearables are designed for long monitoring periods, allowing for extensive data collection on distinctive cough characteristics. Through fully automated analysis, these devices enable healthcare professionals to deliver accurate diagnoses and create personalized treatment plans for patients. C-mo's solutions address key use cases throughout the patient management lifecycle, ensuring that both patients and clinicians benefit from enhanced diagnostic capabilities in the realm of respiratory health.

Trutino Biosciences is a biopharmaceutical company focused on developing innovative cytokine therapies for cancer treatment. Founded in 2017 and based in San Diego, California, Trutino utilizes its proprietary On-Demand-Cytokine (ODC) platform technology to create therapeutic candidates that can be delivered in an inactive form, which are then activated locally at the tumor site. This approach aims to minimize the severe toxicity commonly associated with traditional cytokine therapies while potentially enhancing treatment efficacy, both as standalone therapies and in combination with other modalities. The company's immuno-oncology drugs are designed to specifically target and destroy cancer cells by stimulating tumor-specific immune responses, providing a promising avenue for improving patient outcomes in cancer care.

ArrePath is a drug discovery company focused on developing therapies to combat antimicrobial resistance, a significant global health challenge. The company operates a platform that facilitates the discovery of new anti-infective medicines by targeting multiple pathways in disease processes. This innovative approach aims to enhance the efficacy of treatments while minimizing risks associated with the drug development process. By improving the treatment options available for drug-resistant infections, ArrePath seeks to assist healthcare professionals in managing chronic ailments and reducing patient recovery times.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Optina Diagnostics Inc. is a Canadian company focused on developing innovative technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Founded in 2010 and headquartered in Montréal, the company employs advanced retinal imaging and artificial intelligence to provide non-invasive diagnostic tests for under-diagnosed diseases. Optina Diagnostics' retinal imaging test identifies key patient features that assist healthcare professionals in evaluating health status and disease risk, enabling timely and appropriate care. The company's imaging systems not only facilitate the detection of Alzheimer's-related biomarkers, such as beta-amyloid plaques, but also address other conditions like age-related macular degeneration and diabetic retinopathy. By enhancing brain health assessment, Optina Diagnostics aims to deliver critical information early in the disease progression, ultimately improving patient outcomes.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

xCures, Inc. is a healthcare technology company founded in 2018 and based in Los Altos, California, focused on transforming cancer treatment through its innovative AI-based precision oncology platform. The company addresses the challenges of traditional drug-centric treatment development by integrating cancer research and patient care. Its platform operates as a perpetual trial, continuously capturing Real World Evidence (RWE) from patients and treatments, allowing for real-time learning and adaptation. By coordinating treatment recommendations across various institutions, xCures ensures that patients receive personalized treatment options tailored to their specific needs. Additionally, the platform organizes insights from tumor boards, leveraging machine learning to assist healthcare professionals in making informed decisions. This approach not only enhances the effectiveness of cancer care but also aims to reduce the time and cost associated with drug development, ultimately improving patient outcomes.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies aimed at treating hearing loss. Founded in 2018, the company's innovative technology targets sensorineural hearing loss by replacing damaged or dead sensory cells in the inner ear, allowing for the potential restoration of hearing in affected patients. Through its advancements in cell therapy, Rinri Therapeutics seeks to provide effective solutions for individuals suffering from hearing impairments.

Delonix Bioworks Ltd. is a biotechnology company focused on developing innovative solutions in synthetic biology for healthcare. The company designs and engineers microbial strains to create medicines targeting infectious diseases, cancer, and other medical conditions. Delonix Bioworks is particularly known for its advancements in vaccination technology, which aims to address antimicrobial-resistant infections by enhancing traditional vaccine research. By leveraging synthetic biology, Delonix Bioworks seeks to provide more effective treatments for healthcare providers and improve patient outcomes.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Labor Dr. Merk & Kollegen GmbH, established in 1971, specializes in providing high-quality diagnostic solutions for the medical field. The company has developed significant expertise in biotechnology, virology, microbiology, and toxicology, offering its knowledge to external clients, particularly in the pharmaceutical and medical device sectors. Labor Dr. Merk & Kollegen excels in biosafety testing, employing a variety of GMP and GLP compliant methods for preclinical studies and quality control of final products. Their services encompass contract manufacturing, process development, and testing in areas such as viral gene therapeutics, oncolytic viral therapeutics, vaccines, and immunology. The company prides itself on its highly qualified team, which offers personalized consultation throughout the study design and testing process, ensuring reliable and cost-effective solutions tailored to client needs.

Perfood GmbH, founded in 2017 and headquartered in Lübeck, Germany, specializes in digital therapeutics focused on personalized nutrition. The company employs advanced algorithms and a proprietary dataset to develop therapeutic solutions that aid in weight management and migraine relief. By leveraging sensors, lab results, and comprehensive analyses, Perfood creates tailored dietary plans that address the root causes of health issues. Its digital platform delivers these personalized interventions in an engaging manner, ensuring accessibility for all patients. The company's approach aims to provide drug-like effectiveness without the side effects associated with conventional medications.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.

Libra Therapeutics, Inc. is a biotechnology company based in San Diego, California, that specializes in developing novel disease-modifying therapeutics aimed at addressing neurodegenerative diseases. Founded in 2019, the company focuses on restoring cellular balance disrupted by these conditions. Its therapeutic platform utilizes distinct molecular approaches to enhance autophagy, allowing for the rapid clearance of toxic proteins and the reduction of neurotoxic protein production. Libra Therapeutics targets multiple neurodegenerative disorders, including amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease, with the intention of offering effective treatments that mitigate the impact of these debilitating ailments.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Aignostics GmbH is a Berlin-based company founded in 2018 that specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics, employing patented technology to reverse-engineer conventional AI systems, thereby addressing their “black-box” limitations. Aignostics' platform generates explainable diagnostic results presented as precise heatmaps and image overlays, which facilitate the verification process for pathologists. This capability is crucial in ensuring accurate diagnoses, particularly in the context of discovering and validating biomarkers for cancer and other complex diseases. By improving the understanding of tissue-based biomarkers, Aignostics aims to significantly advance the diagnosis and treatment of various conditions, thereby supporting the broader goals of precision medicine and drug development.

Bodyport Inc. is a healthcare technology company based in San Francisco, California, founded in 2015. It specializes in manufacturing sensor-fitted weighing scales tailored for cardiac patients. Bodyport offers a biomarker-driven virtual clinic aimed at the prevention and management of heart disease. Its innovative device measures critical health indicators, including blood pressure, heart rate, heart rate variability, and arterial stiffness, all through sensors in the user's feet. This technology enables the detection of early signs of cardiovascular disease and supports care teams in assessing patients' overall health status. Additionally, Bodyport provides an online patient portal and educational materials to enhance patient engagement and understanding of their health.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Proxygen is a biotechnology company focused on developing innovative therapies for cancer and other life-threatening diseases. The company utilizes molecular glue degraders, a novel approach that targets and eliminates disease-causing proteins by reprogramming the natural protein recycling machinery present in cells. This method represents a significant shift from traditional therapies that merely inhibit harmful proteins. By harnessing advanced technology and expertise, Proxygen is pioneering the identification and development of novel glue degraders at scale, thus expanding the potential of the druggable target space. This positions Proxygen at the forefront of drug discovery, aiming to transform treatment options for incurable diseases.

Global Stem Cell Technology is a veterinary biotechnology company specializing in the development and production of advanced stem cell products for horses and dogs. The company focuses on blood-derived mesenchymal stem cells designed for clinical applications in animals, translating regenerative medicine into practical solutions. By prioritizing animal welfare, Global Stem Cell Technology aims to enhance the health and treatment options available for pets and equines through innovative stem cell therapies.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

DiogenX is a preclinical stage biotechnology company based in Marseille, France, with research facilities in Nice. Founded in 2019, it specializes in developing therapeutic solutions for diabetic patients, focusing on pancreatic beta-cell modulators for the treatment of both Type 1 and Type 2 diabetes. The company aims to create a candidate molecule that regenerates pancreatic insulin-producing cells, which could significantly improve the quality of life and survival rates for individuals with diabetes. This innovative approach has the potential to become a groundbreaking therapy for beta-cell regeneration in diabetes management, stemming from research conducted in the laboratory of Dr. Patrick Collombat.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.

Northern Biologics Inc., established in 2014 and headquartered in Toronto, Canada, is an early-stage biologics company focused on developing antibody-based therapeutics for oncology and fibrosis. The company employs state-of-the-art phage display technology, originally developed at the University of Toronto, to discover novel therapeutic antibodies targeting challenging cancer and fibrosis pathways. Northern Biologics operates as a subsidiary of Boehringer Ingelheim International GmbH since May 2020, following its strategic collaboration with Celgene Corporation.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

Actym Therapeutics, Inc. is an immunotherapy company based in Berkeley, California, dedicated to the discovery and development of innovative therapies for cancer treatment. Founded in 2017, the company has developed a unique microbial-based immunotherapeutic platform known as STACT (S. Typhimurium-Attenuated Cancer Therapy). This platform is designed to specifically target and enrich within various solid tumors while sparing healthy tissues. In preclinical studies, STACT has shown the capability to deliver multiplexed immuno-modulatory payloads directly to immune cells residing within tumors. This approach addresses significant challenges faced by conventional therapies, particularly systemic toxicities associated with intravenous dosing. By combining multiple payloads within a single therapy, STACT aims to engage various biological pathways, potentially enhancing treatment efficacy. Actym's commitment to overcoming the limitations of existing cancer therapies positions it as a promising player in the biopharmaceutical field.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Abalos Therapeutics GmbH is a biotechnology company based in Essen, Germany, focused on the development of immuno-oncology therapeutics. Established in 2019, the company specializes in creating arenavirus-based drug candidates aimed at activating immune responses against cancerous tumors and metastases. Utilizing its proprietary Fast Evolution platform, Abalos Therapeutics generates virus strains with optimized anti-tumoral properties. The company's innovative approach to virotherapy seeks to harness the immune stimulation capabilities of arenaviruses, enabling the immune system to specifically target and eliminate malignant tumor tissue. Through its advanced therapeutic candidates, Abalos Therapeutics aims to provide new treatment options for cancer patients.

T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of innovative bacteria-based therapies aimed at treating cancer patients. T3 Pharmaceuticals is committed to addressing the significant unmet need for novel cancer treatments by leveraging its proprietary protein delivery platform, which utilizes the bacterial type III secretion system. This approach enables the development of highly specific and efficient immuno-oncology therapies designed to target solid tumors. Through its work, T3 Pharmaceuticals aims to enhance the quality of life for cancer patients and improve treatment outcomes.

Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Dopavision GmbH, founded in 2017 and based in Berlin, Germany, specializes in developing a digital therapeutic aimed at treating myopia, commonly known as shortsightedness. This condition impacts approximately one in three individuals globally and has seen a significant rise in prevalence over the past two decades. The company's innovative approach involves delivering light stimulation to specific photosensitive cells in the retina, which helps modulate dopamine levels—a neurotransmitter crucial for regulating eye growth. By focusing on children and adolescents, Dopavision aims to create a clinically validated therapy that can effectively slow myopia progression. The therapeutic solution is designed to be seamlessly integrated with smartphone technology, allowing for an accessible and user-friendly treatment option.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies aimed at treating hearing loss. Founded in 2018, the company's innovative technology targets sensorineural hearing loss by replacing damaged or dead sensory cells in the inner ear, allowing for the potential restoration of hearing in affected patients. Through its advancements in cell therapy, Rinri Therapeutics seeks to provide effective solutions for individuals suffering from hearing impairments.

AgomAb Therapeutics N.V., based in Gent, Belgium, specializes in the development of molecular therapies aimed at regenerating damaged tissues. The company focuses on creating agonistic monoclonal antibodies, known as agomAbs, which are designed to stimulate molecular and cellular repair mechanisms. These therapies have the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases. AgomAb targets biologically validated pathways, including Transforming Growth Factor β and Hepatocyte Growth Factor, while employing specialized capabilities in organ-specific small molecules and high-affinity antibodies. The company boasts a diversified clinical pipeline addressing various fibrotic conditions and possesses comprehensive research and development expertise, alongside a strong track record in business development.

ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

MabVax Therapeutics is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative anti-cancer immunotherapies. The company leverages two main technology platforms: one involves proprietary vaccines developed at Memorial Sloan-Kettering Cancer Center, with two lead cancer vaccines currently in Phase II clinical trials targeting soft tissue sarcoma and ovarian cancer, both of which have received substantial federal grant support. The second platform is an internally developed human antibody discovery system, which focuses on the immune responses from patients who have been vaccinated against specific cancers. MabVax's leading human antibody candidate is in preclinical evaluation for potential applications in treating colon, pancreatic, and breast cancers, also backed by federal funding. The company aims to address significant unmet needs in cancer treatment through its innovative approaches and pipeline of human monoclonal antibody products.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Acousia Therapeutics GmbH is a biotechnology company based in Tübingen, Germany, focused on developing innovative treatments for hearing loss. Established in 2012, the company specializes in identifying small molecules that can be applied locally to protect or restore hearing function. Acousia's approach centers on stimulating the regeneration of sensory hair cells in the inner ear, which are crucial for hearing. This regenerative capability is achieved by leveraging supporting cells that can replace lost hair cells. The company's therapeutic candidates aim to address hearing loss caused by various factors, such as noise exposure, ototoxic medication, and sudden deafness, and also hold potential for treating age-related hearing decline.

Brainomix Limited is a medical technology company based in Oxford, United Kingdom, that specializes in developing imaging biomarkers and software solutions for neurological and cerebrovascular disorders. Founded in 2010 as a spin-out from the University of Oxford, Brainomix focuses on enhancing clinical decision-making through its AI-powered products. Its flagship offering, e-Stroke, comprises a suite of tools that provide real-time interpretation of brain scans, enabling healthcare professionals to make informed treatment decisions for stroke patients more efficiently. This includes e-ASPECTS, which automates the scoring of brain images to identify early stroke damage, and e-CTA, which standardizes the detection of large vessel occlusions. Additionally, e-Mismatch provides a multi-vendor post-processing solution for MRI and CT scans, enhancing the assessment of stroke damage. By leveraging advanced algorithms and large data analytics, Brainomix aims to improve patient outcomes by ensuring timely and appropriate treatment for stroke patients worldwide.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

Aelin Therapeutics is a privately held Belgian biotherapeutics company founded in 2017, based in Heverlee. The company develops antibiotics and therapeutics using its proprietary Pept-in technology, which leverages protein aggregation to induce functional knockdown of target proteins. This approach allows for the rational design of novel biotherapeutics that can address undruggable human targets and combat resistant bacteria like Methicillin-resistant Staphylococcus aureus (MRSA). Aelin Therapeutics' platform offers a unique mode of action and intracellular target space, differentiating it from traditional small molecule drugs or protein-based therapeutics. The company's technology has shown applications in various areas including bacteria, cancer cells, fungi, viruses, and plant cells, with supporting preclinical Proof of Concept data published in high-impact journals such as Science.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, founded in 2016. The company specializes in developing non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a critical microRNA responsible for pathological changes in the heart resulting from stress or injury. Through its innovative approach, Cardior Pharmaceuticals seeks to address significant unmet medical needs in cardiovascular health.

ImCheck Therapeutics is a biopharmaceutical company based in Marseille, France, that specializes in developing immunotherapeutics aimed at addressing severe unmet medical needs, particularly in the field of immuno-oncology. Founded in 2015, the company focuses on designing and developing immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules. These innovative therapies engage γ9δ2 T cells, a specific type of immune cell, to effectively treat various cancers, including breast, gastric, and ovarian cancers, as well as other solid tumors. Through its advanced research and development efforts, ImCheck Therapeutics seeks to provide next-generation immunotherapeutics for patients suffering from immune-related diseases.

Sentien Biotechnologies, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies aimed at restoring immune system balance and improving treatment options for patients with systemic inflammatory diseases. The company specializes in proprietary cell compositions and Good Manufacturing Practice (GMP) manufacturing methods that enhance the efficacy of cell therapy. Its flagship product, SBI-101, utilizes an extracorporeal device to immobilize Mesenchymal Stromal Cells (MSCs), facilitating sustained and controlled delivery of their therapeutic properties, which include anti-inflammatory and regenerative effects. Additionally, the company offers the Sentinel device, designed to treat patients during dialysis by supplementing their blood with MSC-derived secretions that address immune dysfunction and promote tissue repair. Founded in 2008, Sentien Biotechnologies is headquartered in Medford, Massachusetts.

Sentieon, Inc. is a bioinformatics company based in Mountain View, California, founded in 2014. It specializes in developing and commercializing cloud-based solutions for the life sciences and clinical markets. Sentieon offers a range of bioinformatics tools designed for processing genomics data with a focus on accuracy, efficiency, and quick turnaround times. Its notable products include Sentieon DNAseq, which aids in germline DNA analysis, and Sentieon TNseq, designed for detecting tumor-normal somatic variants. These software-only tools boast scalability and upgradeability, leveraging optimized algorithms to improve computing performance. Sentieon aims to enhance the capabilities of scientists and clinicians by providing precision tools that facilitate comprehensive tumor characterization and other critical bioinformatics processes.

Merial Limited is an animal healthcare company focused on the research, development, and production of pharmaceutical products and vaccines for livestock, pets, and wildlife. The company offers a range of products, including anesthetics, antiparasitics, antimicrobials, and vaccines designed to combat various diseases, such as Newcastle Disease and Avian Flu. Notable products include IVOMEC, used for parasite treatment in cattle, sheep, and swine, and FRONTLINE, which is designed for dogs and cats. Merial serves a diverse clientele, including veterinarians, pet owners, farmers, and food animal producers globally. Founded in 1997 as a joint venture between the animal health assets of Rhône-Poulenc and Merck & Co., the company is headquartered in Duluth, Georgia, and operates in numerous countries worldwide. Merial Limited is now a subsidiary of Sanofi-Aventis, following the acquisition of Rhône-Poulenc and Merck's stake in the company.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

Acousia Therapeutics GmbH is a biotechnology company based in Tübingen, Germany, focused on developing innovative treatments for hearing loss. Established in 2012, the company specializes in identifying small molecules that can be applied locally to protect or restore hearing function. Acousia's approach centers on stimulating the regeneration of sensory hair cells in the inner ear, which are crucial for hearing. This regenerative capability is achieved by leveraging supporting cells that can replace lost hair cells. The company's therapeutic candidates aim to address hearing loss caused by various factors, such as noise exposure, ototoxic medication, and sudden deafness, and also hold potential for treating age-related hearing decline.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

NBE-Therapeutics GmbH is a privately owned biotechnology company based in Basel, Switzerland, founded in 2012. The company specializes in the development of antibody-drug conjugates (ADCs) aimed at treating cancer. NBE-Therapeutics focuses on creating innovative cancer therapies that enhance survival rates and improve the quality of life for patients worldwide. Its proprietary ADC platform is designed to produce potent and safe immune-stimulatory therapies that utilize an anthracycline payload. This approach not only targets tumor cells directly but also promotes a lasting immunological anti-tumor effect, positioning the company as a significant player in the oncology therapeutics field.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.

Rigontec GmbH is a biopharmaceutical company based in Planegg, Germany, focused on developing RNA-based immunotherapeutics for cancer and viral diseases. Founded in 2014, the company is recognized for its innovative approach to immuno-oncology, particularly through its lead compound ImOl100. This compound acts as a stimulator of the immune receptor retinoic acid-inducible gene I (RIG-I), which detects viral RNA and promotes immune responses. ImOl100 serves as a minimal mimic of naturally occurring 3pRNA, a motif commonly found in viral RNAs, and aims to overcome the limitations associated with traditional cancer vaccines and checkpoint inhibitors. As of October 2017, Rigontec operates as a subsidiary of Merck & Co., enhancing its capabilities in the development of effective therapeutic options for patients.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Its proprietary platform leverages computational biology, genomics, and metabolomics to identify specific metabolic alterations that support cancer growth. By creating small molecules that specifically target these reprogrammed metabolic processes, Metabomed aims to halt tumor progression while minimizing harm to surrounding healthy tissues. This innovative approach allows for quicker initiation of treatment and increases the likelihood of successful patient outcomes.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.